Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

  1. Barretina-Ginesta, M.-P.
  2. Monk, B.J.
  3. Han, S.
  4. Pothuri, B.
  5. Auranen, A.
  6. Chase, D.M.
  7. Lorusso, D.
  8. Anderson, C.
  9. Abadie-Lacourtoisie, S.
  10. Cloven, N.
  11. Braicu, E.I.
  12. Amit, A.
  13. Redondo, A.
  14. Shah, R.
  15. Kebede, N.
  16. Hawkes, C.
  17. Gupta, D.
  18. Woodward, T.
  19. O’Malley, D.M.
  20. González-Martín, A.
Revue:
Therapeutic Advances in Medical Oncology

ISSN: 1758-8359,  1758-8340

Année de publication: 2022

Volumen: 14

Type: Article

DOI: 10.1177/17588359221126149 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus